Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
National & Kapodistrian University of Athens, Athens, Greece.
Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.
WHAT IS THIS SUMMARY ABOUT?: This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called newly diagnosed multiple myeloma. Multiple myeloma is a type of cancer in the blood, specifically in plasma cells within the soft, spongy tissue in the center of most bones, called the bone marrow. Researchers wanted to see if adding daratumumab (D) to a standard treatment of three other medicines called VRd, which stands for bortezomib (V), lenalidomide (R), and dexamethasone (d), could stop the multiple myeloma from getting worse and help participants live longer without multiple myeloma.Half of the participants were assigned to the treatment plan with daratumumab; they received D-VRd during initial treatment phases (induction and consolidation), followed by daratumumab as well as lenalidomide (D-R) in the maintenance phase. The other half of participants received treatment without daratumumab; they received VRd induction and consolidation followed by lenalidomide alone (R) maintenance. In addition, all participants were able to receive an autologous stem cell transplant, a procedure used to further help reduce multiple myeloma.
WHAT WERE THE RESULTS?: At the time of this analysis of PERSEUS, about 4 years after participants started the study, participants who received D-VRd treatment followed by D-R maintenance had a better response to treatment (as measured by specific markers of multiple myeloma) and were more likely to be alive and free from their multiple myeloma getting worse in comparison to participants who received VRd followed by R maintenance. Side effects (unwanted or undesirable effects of treatment) in both treatment groups were in line with the known side effects of daratumumab and VRd.
WHAT DO THE RESULTS MEAN?: The results of the PERSEUS study showed that including daratumumab in D-VRd induction/consolidation and D-R maintenance was better for treating multiple myeloma than the current standard VRd treatment followed by R maintenance alone in adults with a new diagnosis of multiple myeloma who were also able to receive an autologous stem cell transplant. Of importance, there were no unexpected side effects in either group. NCT02874742 (GRIFFIN) (ClinicalTrials.gov).
这篇摘要描述了 PERSEUS 研究的首次分析，该研究着眼于从未接受过治疗的多发性骨髓瘤成年患者，也称为新诊断的多发性骨髓瘤。多发性骨髓瘤是一种血液癌，特别是在大多数骨骼中心的柔软、海绵状组织内的浆细胞中，称为骨髓。研究人员想看看在标准的三种药物治疗（VRd，代表硼替佐米[V]、来那度胺[R]和地塞米松[d]）中加入达雷妥尤单抗（D）是否可以阻止多发性骨髓瘤恶化，并帮助患者活得更久而不发生多发性骨髓瘤。一半的参与者被分配到达雷妥尤单抗治疗方案中；他们在初始治疗阶段（诱导和巩固）接受 D-VRd 治疗，然后在维持阶段接受达雷妥尤单抗和来那度胺（D-R）治疗。另一半参与者接受无达雷妥尤单抗治疗；他们接受 VRd 诱导和巩固治疗，然后单独接受来那度胺（R）维持治疗。此外，所有参与者都能够接受自体干细胞移植，这是一种进一步帮助减少多发性骨髓瘤的程序。
在 PERSEUS 的这项分析时，大约是参与者开始研究后的 4 年后，接受 D-VRd 治疗然后再接受 D-R 维持治疗的参与者对治疗的反应（通过多发性骨髓瘤的特定标志物测量）更好，并且与接受 VRd 然后再接受 R 维持治疗的参与者相比，他们更有可能存活并且没有多发性骨髓瘤恶化。两组治疗的副作用（治疗的不良或不期望的影响）与达雷妥尤单抗和 VRd 的已知副作用一致。
PERSEUS 研究的结果表明，与目前的标准 VRd 治疗（新诊断的多发性骨髓瘤患者在能够接受自体干细胞移植的情况下，单独接受 R 维持治疗）相比，在接受自体干细胞移植的新诊断多发性骨髓瘤患者中，在 D-VRd 诱导/巩固和 D-R 维持中加入达雷妥尤单抗在治疗多发性骨髓瘤方面更好。重要的是，两组均未出现意外的副作用。NCT02874742（GRIFFIN）（ClinicalTrials.gov）。
